Prostacyclin (PGI2) plays a major role in preventing thrombin-induced platelet adherence to the vascular endothelium.
Answers are grounded in this paper and cite their sources.
PGI2 may limit thrombin-induced platelet adherence; hypothesis-generating in this animal model and requires human validation before clinical consideration.
The intact vascular endothelial surface is considered to be "non-thrombogenic", and blood platelets usually fail to adhere to ti. In this role, the endothelium serves to maintain the integrity of the vascular system by preventing the escape of blood and by preventing the build-up of solid thrombus within the vessel, which would compromise blood flow. A possible explanation for the non-thrombogenic effect of the endothelium is the presence of prostacyclin (PGI2), the potent inhibitor of platelet aggregation and adherence, which is produced and released by the endothelium in response to various stimuli. Removal of PGI2 from the endothelium by four different methods did not increase baseline platelet adherence, but did increase thrombin-induced platelet adherence from 4 to 60%. Addition of exogenous PGI2, at low concentrations reversed the enhanced thrombin-induced platelet adherence under these conditions. Although it is unlikely that prostacyclin is the sole factor regulating platelet adherence to the endothelium, it appears to play a major role in the interaction of platelets with components of the blood vessel wall.
No takes yet. Share an insight, caveat, or question.
Hoak et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: